The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operati
about
Nuclear imaging for functional evaluation and theragnosis in liver malignancy and transplantationMetabolic genes in cancer: their roles in tumor progression and clinical implicationsParametric images via dynamic 18F-fluorodeoxyglucose positron emission tomographic data acquisition in predicting midterm outcome of liver metastases secondary to gastrointestinal stromal tumours.Use of computed tomography in the management of colorectal cancer.Restaging of colorectal cancer and PET/CT.PET imaging of bacterial infections with fluorine-18-labeled maltohexaose.Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases.Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis.Desmoid tumour (aggressive fibromatosis) of the colon mimics malignancy on dual time-point 18F-FDG PET/CT imaging.Evaluation of cancer treatment in the abdomen: Trends and advances.PET/CT imaging in the diagnosis, staging, and follow-up of colorectal cancer.The current role of PET-CT in the characterization of hepatobiliary malignancies.Colorectal cancer: prognostic role of 18F-FDG-PET/CT.Advances in the surgical treatment of colorectal cancer liver metastases through ultrasound.Current treatment for colorectal liver metastasesPositron emission tomography in hepatobiliary and pancreatic malignancies: a review.Positron emission tomography in malignancies of the liver, pancreas and biliary tract - indications and potential pitfalls.High dose stereotactic body radiotherapy using three fractions for colorectal oligometastases.Imaging patterns and focal lesions in fatty liver: a pictorial review.Complete radiological response of colorectal liver metastases after chemotherapy: what can we expect?Complete radiologic and metabolic response of colorectal liver metastasis after neoadjuvant chemotherapy: to resect or not?Multiple focal nodular hyperplasias induced by oxaliplatin-based chemotherapy.Positron emission tomography scan for a hepatic mass.What is the most accurate whole-body imaging modality for assessment of local and distant recurrent disease in colorectal cancer? A meta-analysis : imaging for recurrent colorectal cancer.Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease.Preoperative staging of patients with liver metastases of colorectal carcinoma. Does PET/CT really add something to multidetector CT?Intraoperative liver ultrasound still affects surgical strategy for patients with colorectal metastases in the modern era.Usefulness of contrast-enhanced intraoperative ultrasonography (CE-IOUS) in patients with colorectal liver metastases after preoperative chemotherapy.Diagnostic performance of CT, gadoxetate disodium-enhanced MRI, and PET/CT for the diagnosis of colorectal liver metastasis: Systematic review and meta-analysis.Effect of chemotherapy on the impact of FDG-PET/CT in selection of patients for surgical resection of colorectal liver metastases: single center analysis of PET-CAM randomized trial.(18)F-FDG Uptake at the Surgical Margin after Hepatic Resection: Patterns of Uptake and Differential Diagnosis.Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy.Accuracy of multislice liver CT and MRI for preoperative assessment of colorectal liver metastases after neoadjuvant chemotherapy.Re-evaluation of detectability of liver metastases by contrast-enhanced CT: added value of hepatic arterial phase imaging.Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist(®))-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: initial experience in a single centre.Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab.
P2860
Q33594891-1545EF13-A6E0-464D-90DD-C08A5A863589Q33772469-6F3741A9-F293-4EF9-9346-12C0FA75DA1EQ33844776-F7E79905-FF13-423B-99A3-1009D32F1A44Q34390519-8247AFA2-6BFC-4B1F-BB7B-64706C87A28BQ35233507-A9AEA994-A5B1-4B4E-B9F8-037B57E763DFQ35602940-66692B1F-7D98-41B6-A221-95DC76A8034EQ35761121-9CAF27BB-B409-4DAE-9F2C-E1E6B13224CCQ36208221-0C1B54C8-3622-47C5-A465-C177A36D003FQ36325581-5579A56F-B4C2-4939-A118-46C1A52578FBQ36832118-77646588-6301-48DD-80DC-D324EFF414F1Q37292835-144C5D6A-5F60-48C2-86E5-B1553D75C66BQ37546832-D5D8F161-F040-4EC3-9A76-B21ABA9D4450Q37918895-1642EEAB-892D-4D97-9307-0D991F4A09ECQ37923362-86994495-DFE2-41A9-B868-800B677BDED8Q37951004-82BB4367-67AE-4CEC-BFA5-F00CAF8D448CQ37998654-B8599233-15FE-46A4-9F54-F5C901105642Q38059510-64723B22-D669-454D-940D-0DB08BF0BEC0Q38465908-ABD81BD2-5B29-43EC-A5F1-524BB14FD00BQ39045054-1B48308B-C0BF-4401-92DB-9455B9A7CC41Q39754325-E379201E-B4E7-43C5-92AE-EE3E475FC802Q41991824-3582B986-186C-4D2C-8B0B-7011BFECB874Q42006843-CB511D75-9CAB-4FD2-8BE1-D5FB593BF4DCQ42035603-194C96B5-F9EA-47CB-8F4A-BA897804FAF6Q42780962-E6936028-B6BC-4DEF-9E06-554E1D51F7B0Q45141490-58986112-66BF-4317-B83E-BEBE7F13A55EQ45172417-F79B359E-B9DE-4395-B93D-8FA7706AD389Q45853119-EAC3961A-1B09-4441-AAC0-1D2FF84841F5Q45901974-CC0B7D2D-4B3B-4DA8-9720-AC4746A9D165Q47992587-29FEFFD0-E9AB-4FBE-9462-BCCB1B05B316Q52962069-6AD4A677-90C8-412A-A754-74A02975C40FQ53026521-8EDC131C-89AE-496E-BAE5-EBAEFED5F521Q53077760-1209C550-EB20-4F36-8A8D-2D952949208FQ53080178-6D333D23-D550-47D0-BBC9-C1565B32D983Q53144869-A53E73A7-F3AD-4713-8DEE-CA9AAE8B4AEEQ53170580-C858F04F-ABAC-4D43-8126-0AC0AB694062Q53178962-400D94E4-53F3-4B6F-A9E3-042C0EA1FF80
P2860
The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operati
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The role and limitations of 18 ...... erapy: comparison with operati
@ast
The role and limitations of 18 ...... erapy: comparison with operati
@en
type
label
The role and limitations of 18 ...... erapy: comparison with operati
@ast
The role and limitations of 18 ...... erapy: comparison with operati
@en
prefLabel
The role and limitations of 18 ...... erapy: comparison with operati
@ast
The role and limitations of 18 ...... erapy: comparison with operati
@en
P2093
P2860
P1476
The role and limitations of 18 ...... erapy: comparison with operati
@en
P2093
Arie Figer
Einat Even-Sapir
Einat Shmueli
Joseph M Klausner
Menahem Ben-Haim
Nir Lubezky
Ravit Geva
Richard Nakache
P2860
P2888
P304
P356
10.1007/S11605-006-0032-8
P577
2007-04-01T00:00:00Z